Skip to content

Study · Randomized controlled trial · n = 245 · 1992

4 results

Does the somatostatin analogue octreotide protect against ERCP induced pancreatitis?

Binmoeller KF, Harris AG, Dumas R, Grimaldi C, Delmont JP

Gut1 Aug 1992Cited by 66 (Europe PMC)

PMID1383099 (opens in a new tab)PMCIDPMC1379457 (opens in a new tab)DOI10.1136/gut.33.8.1129 (opens in a new tab)PepBankPUB-01383099
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialSafety outcome

    In ERCP patients, octreotide and saline groups did not differ significantly in median serum amylase activity at baseline, eight, and 24 hours.

    In plain wordsIn ERCP patients, serum amylase did not differ significantly between octreotide and saline at baseline, eight, and 24 hours.

    Peptide
    Octreotide
    Outcome
    No significant changeSerum amylase activity
    Study

    n = 245

    Comparator
    Isotonic saline
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    100 micrograms, given intravenously five minutes before ERCP and subcutaneously 45 minutes after ERCP · intravenous then subcutaneousAs given in this study (human).

    Source sentences

    Summary
    There were no significant differences in the median serum amylase and lipase activities at baseline, eight, and 24 hours after ERCP.
    2 context sentences
    Summary · context
    Altogether 245 patients were randomised to receive either octreotide or isotonic saline.
    Summary · context
    Octreotide (100 micrograms) was administered intravenously five minutes before ERCP and subcutaneously 45 minutes after ERCP.
  2. 02HumanRandomized controlled trialSafety outcome

    In ERCP patients, octreotide and saline groups did not differ significantly in median serum lipase activity at baseline, eight, and 24 hours.

    In plain wordsIn ERCP patients, serum lipase did not differ significantly between octreotide and saline at baseline, eight, and 24 hours.

    Peptide
    Octreotide
    Outcome
    No significant changeSerum lipase activity
    Study

    n = 245

    Comparator
    Isotonic saline
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    100 micrograms, given intravenously five minutes before ERCP and subcutaneously 45 minutes after ERCP · intravenous then subcutaneousAs given in this study (human).

    Source sentences

    Summary
    There were no significant differences in the median serum amylase and lipase activities at baseline, eight, and 24 hours after ERCP.
    2 context sentences
    Summary · context
    Altogether 245 patients were randomised to receive either octreotide or isotonic saline.
    Summary · context
    Octreotide (100 micrograms) was administered intravenously five minutes before ERCP and subcutaneously 45 minutes after ERCP.
  3. 03HumanRandomized controlled trialSafety outcome

    In ERCP patients, clinical pancreatitis developed in three octreotide patients versus two placebo patients.

    In plain wordsIn ERCP patients, clinical pancreatitis developed in three octreotide patients versus two placebo patients.

    Peptide
    Octreotide
    Outcome
    IncreaseClinical pancreatitis
    Study

    n = 245

    Comparator
    Isotonic saline
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    100 micrograms, given intravenously five minutes before ERCP and subcutaneously 45 minutes after ERCP · intravenous then subcutaneousAs given in this study (human).

    Measurements

    Patients with clinical pancreatitis
    3 patients
    octreotide group
    Patients with clinical pancreatitis
    2 patients
    placebo group
    Patients with clinical pancreatitis
    5 patients
    both groups combined
    Patients with clinical pancreatitis
    2%
    both groups combined

    Source sentences

    Summary
    Five patients (2%) developed clinical pancreatitis--three in the octreotide and two in the placebo groups.
    2 context sentences
    Summary · context
    Altogether 245 patients were randomised to receive either octreotide or isotonic saline.
    Summary · context
    Octreotide (100 micrograms) was administered intravenously five minutes before ERCP and subcutaneously 45 minutes after ERCP.
  4. 04HumanNon-randomized trialSafety outcome

    Among ERCP patients without pancreatitis, abdominal pain occurred in 21 octreotide patients versus 23 placebo patients.

    In plain wordsAmong ERCP patients without pancreatitis, abdominal pain occurred in 21 octreotide patients versus 23 placebo patients.

    Peptide
    Octreotide
    Outcome
    DecreaseAbdominal pain excluding pancreatitis
    Study

    n: not reported in source

    Comparator
    Isotonic saline
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    100 micrograms, given intravenously five minutes before ERCP and subcutaneously 45 minutes after ERCP · intravenous then subcutaneousAs given in this study (human).

    Measurements

    Patients with abdominal pain after ERCP
    21 patients
    octreotide group, excluding patients with pancreatitis
    Patients with abdominal pain after ERCP
    23 patients
    placebo group, excluding patients with pancreatitis
    Patients with abdominal pain after ERCP
    43 patients
    both groups combined, excluding patients with pancreatitis
    Patients with abdominal pain after ERCP
    18%
    both groups combined, excluding patients with pancreatitis

    Source sentences

    Summary
    Excluding patients who developed pancreatitis, 43 (18%) developed abdominal pain after ERCP--21 in the octreotide and 23 in the placebo groups.
    2 context sentences
    Summary · context
    Altogether 245 patients were randomised to receive either octreotide or isotonic saline.
    Summary · context
    Octreotide (100 micrograms) was administered intravenously five minutes before ERCP and subcutaneously 45 minutes after ERCP.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.